Fatty Liver Disease Now Affects 4 in 10 U.S. Adults
By Ernie Mundell HealthDay Reporter
WEDNESDAY, Nov. 13, 2024 -- Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns.
By 2018, federal data showed that 42% of adults had some form of fatty liver disease -- higher than prior estimates, according to a team led by Dr. Juan Pablo Arab, a liver specialist with at Virginia Commonwealth University's Institute for Liver Disease and Metabolic Health, in Richmond.
Hispanic adults were at especially high risk, the team noted, with nearly half (47%) affected.
The findings were published recently in the journal Nature Communications Medicine.
As Arab's team explained, fatty liver disease comes in many forms, but involves the slow buildup of fat deposits within the blood-cleansing organ.
There are three main kinds of fatty liver disease: metabolic dysfunction-associated steatotic liver disease (MASLD, caused by metabolic factors such as obesity and diabetes), alcohol-associated liver disease (ALD) and a combination of both syndromes, called MetALD.
According to the American Liver Foundation, advanced liver disease can cause jaundice, fluid retention, eye trouble and brain dysfunction. Over time, liver failure and fatal kidney complications can also occur.
The new study was based on 2017-2018 data from the National Health and Nutrition Examination Survey, looking at the health of 5,523 adults.
MASLD is by far the most common form of liver disease, affecting 42% of adults. ALD and MetALD affect much lower percentages -- 1.7% and 0.6% of adults, respectively.
Rates of fatty liver disease were more common in men than women, and rose with age.
The high rate of MASLD among Hispanics was surprising, given that one 2014 study found a much lower rate of Hispanics, 29%, had the disease at that time.
The Virginia researchers say genetics, as well as relatively high rates of obesity and diabetes, could explain why Hispanics are especially prone to MASLD.
For reasons that aren't clear, Black adults had the lowest rate of fatty liver disease.
What's driving the overall surge in MASLD among adults? According to the researchers, obesity and type 2 diabetes are key factors.
About 65% of overweight adults have MASLD, the team said, rising to 90% among morbidly obese people.
At the same time, up to 70% of patients with type 2 diabetes also have MASLD, Arab's group noted.
“This study highlights a significant health issue that affects a large portion of the U.S. population, and it shows that certain groups are at a higher risk,” Arab said in a university news release. “We hope these findings will guide more targeted health interventions to reduce the burden of liver disease, especially in high-risk communities.”
Sources
- Virginia Commonwealth University, news release, Nov. 12, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Diabetes Drug, Dapagliflozin, Effective For Fatty Liver Disease
FRIDAY, June 6, 2025 — A repurposed diabetes drug can be an effective tool against fatty liver disease, a new clinical trial has found. Dapagliflozin helped people reduce...
More U.S. Teens Are Now Taking Wegovy for Weight Loss
THURSDAY, June 5, 2025 — More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment. But experts...
Weight Stigma Tied To Lingering Depression, Anxiety After Weight-Loss Surgery
THURSDAY, June 5, 2025 — People who get weight-loss surgery experience an improvement in their mental health, but not because of the weight they lose, a new study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.